

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 November 2010 (04.11.2010)

PCT

(10) International Publication Number
WO 2010/126732 A1

(51) International Patent Classification:
C07K 14/00 (2006.01) **C40B 30/08** (2006.01)

(21) International Application Number:
PCT/US2010/031569

(22) International Filing Date:
19 April 2010 (19.04.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/173,687 29 April 2009 (29.04.2009) US

(71) Applicant (for all designated States except US):
TRUSTEES OF DARTMOUTH COLLEGE [US/US];
Technology Transfer Office, 11 Rope Ferry Road,
Hanover, NH 03755-1404 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KULL, F., Jon** [US/
US]; 8 Ridge Road, Enfield, NH 03748 (US).
COCHRAN, Jared, C. [US/US]; 45 Forest Lane, Brad-
ford, VT 05033 (US).

(74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: HYBRID PROKARYOTIC-EUKARYOTIC TUBULINS AND USE THEREOF

(57) Abstract: The present invention embraces *hybrid Prosthecobacter- eukaryotic* tubulin proteins and use thereof for identify-
ing agents that modulate the activity of tubulin.



WO 2010/126732 A1

-1-

HYBRID PROKARYOTIC-EUKARYOTIC TUBULINS AND USE THEREOF**Introduction**

[0001] This application claims priority to U.S. Patent Application Serial No. 61/173,687, filed April 29, 2009, the content of which is incorporated herein by reference in its entirety.

[0002] This invention was made with government support under grant number F32 AR054653 awarded by the National Institutes of Health. The government has certain rights in the invention.

Background of the Invention

[0003] Microtubules, along with actin and intermediate filaments, are the three components of the cellular cytoskeleton. Microtubules are hollow tube-like structures composed of linear protofilaments that are assembled from dimers of α - and β -tubulin. These rigid structures are larger than both actin and intermediate filaments, have an outer diameter of about 25 nm with a luminal diameter of about 18 nm (Howard (2001) *Mechanics of Motor Proteins and the Cytoskeleton* (Sinauer Associates, Inc.)), and can be between 1 μ m and 1 mm long (Wade & Chretien (1993) *J. Struct. Biol.* 110:1-27). Microtubules are dynamic filaments, able to polymerize and depolymerize in a regulated manner, and are therefore used in many cellular processes (Desai & Mitchison (1997) *Ann. Rev. Cell Dev. Biol.* 13:83-117; Mitchison & Kirschner (1984) *Nature* 312:237-242). One necessary process is the formation of the mitotic spindle, where microtubules play a critical role in chromosome segregation. In addition, microtubules act as the protein tracks for molecular motor proteins, such as kinesin and dynein.

-2-

[0004] Tubulin exists as a stable heterodimer containing a non-exchangeable (α -subunit) and exchangeable (β -subunit) guanine nucleotide (GTP) binding site (Amos & Schlieper (2005) *Curr. Opin. Struct. Biol.* 10:236-241). In a growing microtubule, dimers add faster to the plus end. GTP in the β -subunit is slowly hydrolyzed to GDP, but the GTP in the α -subunit is sterically blocked from exchange by the β -subunit, and its GTP is never hydrolyzed (Downing & Nogales (1998) *Curr. Opin. Cell Biol.* 10:16-22; Lowe, et al. (2001) *J. Mol. Biol.* 313:1045-1057; Nogales, et al. (1999) *Cell* 96:79-88; Nogales, et al. (1995) *Nature* 375:424-427). If GTP-bound α/β dimers add to a growing microtubule faster than hydrolysis proceeds, it produces what is known as a GTP cap, which stabilizes the end of the microtubule. Subsequently, if hydrolysis catches up to the microtubule end, the microtubule becomes unstable and depolymerizes in what is called 'catastrophe'. This rather unique behavior of microtubules is referred to as dynamic instability (Desai & Mitchison (1997) *Ann. Rev. Cell Devel. Biol.* 13:83-117; Mitchison & Kirschner (1984) *Nature* 312:237-242), and can be regulated by various microtubule associated proteins, as well as by regulation of tubulin dimer concentrations.

[0005] Each tubulin subunit is composed of three domains: an N-terminal nucleotide-binding domain, an intermediate domain, and a C-terminal domain, composed of helices $\alpha 11/\alpha 12$ and the acidic C-terminal "tails", which together constitute the binding region for microtubule-based motor proteins (Lowe, et al. (2001) *J. Mol. Biol.* 313:1045-1057; Nogales, et al. (1995) *Nature* 375:424-427). The α/β tubulin heterodimers interact with each other longitudinally (head-to-tail) to form long, rod-like polymers called protofilaments. Between 10 and 15 (but generally 13 in

-3-

vivo) parallel protofilaments interact laterally (side-by-side) to form a hollow cylindrical structure. The structural polarity of the microtubule gives rise to different rates of polymerization at either end. The rapidly polymerizing end of the microtubule is designated as the plus-end, while the slow growing end is called the minus-end. Different microtubule-based motor proteins have been shown to move along the microtubule track in one direction or the other, as well as regulating the polymerization and depolymerization dynamics.

[0006] A number of bacterial homologues of tubulin have been identified and structurally characterized. Among these are FtsZ (Lowe & Amos (1998) *Nature* 391:203-206), BtubA/B (Jenkins, et al. (2002) *Proc. Natl. Acad. Sci. USA* 99:17049-17054; Schlieper, et al. (2005) *Proc. Natl. Acad. Sci. USA* 102:9170-9175; Sontag, et al. (2005) *J. Cell Biol.* 169:233-238), TubZ (Chen & Erickson (2008) *J. Biol. Chem.* 283:8102-8109; Larsen, et al. (2007) *Genes Dev.* 21:1340-1352) and RepX (Pogliano (2008) *Curr. Opin. Cell Biol.* 20:19-27). While FtsZ is a very distant relative of eukaryotic α/β tubulin, BtubA/B are more closely related, and may even have been horizontally transferred into bacteria from eukaryotes (Schlieper, et al. (2005) *supra*). BtubA/B proteins form dimers in a manner very similar to α/β tubulin, and these dimers can form protofilaments in a GTP-dependent manner (Schlieper, et al. (2005) *supra*; Sontag, et al. (2005) *supra*). Although microtubule-like structures have not been observed for BtubA/B, the protofilaments are able to associate, forming twisted pairs as well as bundles. The overall protein fold of BtubA/B is very similar to eukaryotic tubulin (~ 1.7 Å root mean square displacement between ~ 360 amino acid α -carbons) despite modest sequence identity (31%-37%). In the crystal

-4-

structure of the BtubA/B dimer, BtubA (corresponding to β -tubulin) was bound to GDP while the nucleotide binding site of BtubB (corresponding to α -tubulin) was empty.

Summary of the Invention

[0007] The present invention features a hybrid *Prostheco bacter*-eukaryotic tubulin A protein with an amino acid sequence having at least 90% sequence identity with the amino acid sequence of *Prostheco bacter* tubulin A, wherein the surface amino acid residues of *Prostheco bacter* tubulin A have been replaced with the corresponding surface amino acid residues of eukaryotic tubulin β . In one embodiment, the *Prostheco bacter* tubulin A is set forth in SEQ ID NO:7. In another embodiment, the eukaryotic tubulin β is mammalian. In a further embodiment, the surface amino acid residues of *Prostheco bacter* tubulin A are set forth in Table 2. In a particular embodiment, the amino acid substitutions of the hybrid protein are set forth in Table 4. A hybrid protein further including a eukaryotic C-terminus is also embraced by the invention, wherein the eukaryotic C-terminus is selected from the group of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15.

[0008] The present invention further features a hybrid *Prostheco bacter*-eukaryotic tubulin B protein with an amino acid sequence having at least 90% sequence identity with the amino acid sequence of *Prostheco bacter* tubulin B, wherein the surface amino acid residues of *Prostheco bacter* tubulin B have been replaced with the corresponding surface amino acid residues of eukaryotic tubulin α . In one embodiment, the *Prostheco bacter* tubulin B comprises SEQ ID NO:8. In another embodiment, the eukaryotic tubulin α is mammalian. In a further embodiment, the surface amino acid residues of *Prostheco bacter* tubulin B are set forth in

-5-

Table 2. In a particular embodiment, the hybrid tubulin B protein has the amino acid substitutions set forth in Table 4. A hybrid tubulin B protein further including a eukaryotic C-terminus is also embraced by the invention, wherein the eukaryotic C-terminus is selected from the group of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.

[0009] An isolated hybrid *Prostheco bacter*-eukaryotic tubulin heterodimer is further featured. The heterodimer of the invention is composed of tubulin proteins with amino acid sequences having at least 90% sequence identity with the amino acid sequences of SEQ ID NO:7 and SEQ ID NO:8, wherein the surface amino acid residues of SEQ ID NO:7 and SEQ ID NO:8 have been replaced with the corresponding surface amino acid residues of eukaryotic tubulin β and tubulin α , respectively. In particular embodiments, the hybrid *Prostheco bacter*-eukaryotic tubulin heterodimer has the amino acid substitutions set forth in Table 4. In further embodiments, the hybrid *Prostheco bacter*-eukaryotic tubulin proteins of the heterodimer further include eukaryotic C-termini.

[00010] Isolated nucleic acid molecules encoding the hybrid tubulin proteins of the invention as well as host cells containing the same are also provided, as is a method for identifying agents that modulate the activity of the *Prostheco bacter*-eukaryotic tubulin heterodimer.

Brief Description of the Drawings

[00011] Figure 1 shows an amino acid sequence alignment of wild-type *Prostheco bacter* tubulin A (Figure 1A) and tubulin B (Figure 1B) subunits. Pdej, *P. dejongeii*; Pdeb, *P. debontii*; Pvan, *P. vanneervanii*; Cons., Conserved residues.

-6-

Detailed Description of the Invention

[00012] Microtubules are a critical component of the cellular cytoskeleton, serving both structural and functional roles. Although their unique characteristics allow them to dynamically grow and shrink in a GTP and tubulin dependent manner, it is clear that active regulation by proteins plays a critical role during the cell cycle. Additionally, microtubule-based motor proteins use microtubules as tracks upon which to move cargo during active transport. Understanding the structural and mechanistic details of protein-microtubule interactions is therefore of paramount importance. Although great progress has been made in studying these interactions, the heterogeneous nature of naturally derived tubulin presents a major challenge to the field. Conventional tubulin is purified from brain tissue, and has significant drawbacks, including the propensity to polymerize at the concentration of protein necessary for high resolution structural studies thereby precluding formation of the protein crystals necessary for structure determination; and tubulin protein purified from natural sources (most commonly bovine or porcine brain) exists in multiple isoforms that are differentially post-translationally modified, and such heterogeneous proteins cannot be crystallized.

[00013] Using a protein engineering approach, the surface of two prokaryotic "tubulin-like" proteins, BtubA and BtubB have now been redesigned to mimic the surface of eukaryotic tubulin by mutating surface amino acid residues to the corresponding amino acids in eukaryotic tubulin. By mutating only surface residues, the hydrophobic core of the heterodimer is not altered thereby allowing folding in the same manner as wild-type heterodimer. This hybrid prokaryotic-eukaryotic tubulin heterodimer provides a

-7-

homogenous tubulin protein preparation for use in biochemical assays and structural research as well as in screening assays for agents that modulate protofilament formation or interactions with motor proteins. In so far as cell division depends on the proper formation of the microtubule-based mitotic spindle, regulators of microtubule dynamics and proteins involved in spindle formation and action are attractive targets for anticancer drugs. The hybrid prokaryotic-eukaryotic tubulin heterodimer of this invention will enable and simplify the investigation of the role of tubulin and the visualization of protein-tubulin interactions, leading to the development of therapeutics against a broad range of diseases.

[00014] According to the present invention, a hybrid prokaryotic-eukaryotic tubulin heterodimer contains prokaryotic tubulin A and B subunits, which have been mutated so that the selected surface amino acid residues of the prokaryotic tubulin A and B subunits have been replaced with the surface residues from eukaryotic tubulin α and β subunits. Hybrid subunits of the invention will possess at least 80% sequence identity, preferably at least 90% sequence identity, more preferably at least 92% sequence identity with native prokaryotic tubulin A and B subunits. Percentage sequence identity is determined, for example, by the Fitch, et al. (1983) *Proc. Nat. Acad. Sci. USA* 80:1382-1386, version of the algorithm described by Needleman, et al. (1970) *J. Mol. Biol.* 48:443-453, after aligning the sequences to provide for maximum homology. Native or wild-type prokaryotic tubulin A and B subunits refer to polypeptides which have not been mutated. In particular embodiments, the prokaryotic tubulin A and B subunits are obtained from a bacterium of the genera *Prostheco bacter*. Native or wild-type *Prostheco bacteri* tubulin A and B

-8-

subunits, also referred to respectively as bTubA and bTubB, are known in the art and have an amino acid sequence as set forth in Table 1.

TABLE 1

<i>Prostheco bacter</i> sp.	Tubulin	GenBank Accession No.	SEQ ID NO:
<i>P. de j onge ii</i>	bTubA	AAO12155	1
	bTubB	AAO12159	2
<i>P. vanneerven ii</i>	bTubA	CAJ14012	3
	bTubB	CAJ14013	4
<i>P. debont ii</i>	bTubA	CAJ14017	5
	bTubB	CAJ14023	6

[00015] In particular embodiments, the native or wild-type *Prostheco bacteri* tubulin A and B subunits have an amino acid sequence as set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively (Figure 1).

[00016] For the purposes of the present invention, surface amino acid residues of tubulin refer to those residues, which upon folding and dimerization, are presented on the exterior of the heterodimer. In this regard, it is the surface residues of the heterodimer that interact with other proteins, e.g., motor proteins. Surface amino acid residues of *Prostheco bacteri* tubulin A and B subunits, which are mutated in accordance the present invention include, but are not limited to, those set forth in Table 2.

TABLE 2

Tubulin Subunit	Surface Residue*
bTubA	157, 160, 162, 164-165, 194-195, 197-199, 268, 348, 409, 411-412, 414-415, 418-419, 421-422, 425-426, 429, 431-432
bTubB	106-108, 191-192, 195, 260, 262-263, 389-392, 399-401, 404-407, 409-410, 413-414, 417, 419-421, 424-426

-9-

* Residue of bTubA or bTubB is with reference to SEQ ID NO:7 or SEQ ID NO:8, respectively.

[00017] A eukaryotic surface residue that corresponds to a prokaryotic surface residue is intended to mean a residue that resides in the same location on both the eukaryotic and prokaryotic proteins. The determination of surface residues can be based upon protein structure analysis derived from three-dimensional crystal structures or predicted secondary and tertiary protein folding. For example, the crystal structure of the bacterial tubulin heterodimer is available under PDB ID: 2BTQ and the bovine tubulin heterodimer under PDB ID: 1TUB. Advantageously, substitution or replacement of surface amino acid residues of prokaryotic tubulin A and tubulin B with corresponding eukaryotic residues allows for the surface of the prokaryotic tubulin to mimic a eukaryotic tubulin heterodimer.

[00018] According to the invention, surface residues of eukaryotic tubulin α and tubulin β can be derived from animal, plant, fungi, or insect tubulin protein sequences. In particular embodiments, surface residues of eukaryotic tubulin α and tubulin β are derived from mammalian tubulin protein sequences. By way of illustration, Table 3 lists the surface residues of bTubA and bTubB which were replaced with the surface residues of bovine tubulin α and tubulin β . It should be noted that the structure of BtubA is most similar to β -tubulin, and BtubB is most similar to α -tubulin. Therefore, substitutions in BtubA are from corresponding residues in bovine tubulin β , whereas substitutions in BtubB are from corresponding residues in bovine tubulin α .

-10-

TABLE 3

bTubA Substitutions*	bTubB Substitutions *
E157S	Y106H
K160R	N107Y
K162E	V108T
G164P	Q191H
E165D	R192T
N194H	D195E
T195Q	F260Y
R197V	G262R
R198E	N263G
S199N	F389Y
S268R	D390A
Y348E	N391K
S409D	H392R
E411M	E399V
Q412E	N400G
N414T	A401E
V415E	S404E
A418S	R405E
S419N	D406G
Q421N	M407E
E422D	A409S
Q425S	K410E
S426E	N413E
V429Q	Q414D
E431Q	T417A
E432D	A419E
	Q420K
	S421D
	D424E
	A425V
	S426G

*Residues are with reference to *P. dejongei* tubulin A and tubulin B.

[00019] Based upon the illustrative amino acid substitutions of bacterial tubulin A and B subunits with the surface residues of tubulin α and β from *Bos taurus* (e.g., Tub α , GENBANK Accession No. NP_001029376; Tub β , GENBANK Accession No. NP_001003900), similar amino acid residue substitutions are made using the surface residues of other eukaryotic tubulin protein sequences. Mammalian tubulin protein sequences are known in the art and include, but are not

-11-

limited to, tubulin from *Rattus norvegicus* (e.g., Tub α , GENBANK Accession No. NP_001019510; Tub β , GENBANK Accession No. NP_001102589); *Mus musculus* (e.g., Tub α , GENBANK Accession No. NP_059075; Tub β , GENBANK Accession No. NP_033476); *Homo sapiens* (e.g., Tub α , GENBANK Accession No. NP_061816; Tub β , GENBANK Accession No. NP_006077); and *Sus scrofa* (e.g., Tub α , GENBANK Accession No. NP_001038009; Tub β , GENBANK Accession No. NP_001107168). Tubulin protein sequences from other eukaryotes are also known in the art and include, but are not limited to, those from plants such as *Zea mays* (e.g., Tub α , GENBANK Accession No. CAD20822; Tub β , GENBANK Accession No. CAA37060), *Arabidopsis thaliana* (e.g., Tub α , GENBANK Accession No. NP_175423; Tub β , GENBANK Accession No. AAM10035), or *Oryza sativa* (e.g., Tub α , GENBANK Accession No. AAG16905; Tub β , GENBANK Accession No. CAA55021); fungi such as *Saccharomyces cerevisiae* (e.g., Tub α , GENBANK Accession No. NP_013625; Tub β , GENBANK Accession No. BAA09202), *Schizosaccharomyces pombe* (e.g., Tub α , GENBANK Accession No. NP_595106; Tub β , GENBANK Accession No. NP_596650), or *Neurospora crassa* (e.g., Tub α , GENBANK Accession No. CAA55940; Tub β , GENBANK Accession No. AAA33617); and insects such as *Drosophila melanogaster* (e.g., Tub α , GENBANK Accession No. NP_476772; Tub β , GENBANK Accession No. NP_523842) or *Bombyx mori* (e.g., Tub α , GENBANK Accession No. NP_001036884; Tub β , GENBANK Accession No. NP_001036965). Exemplary amino acid substitutions of surface amino acid residues of SEQ ID NO:7 and SEQ ID NO:8 with corresponding eukaryotic amino acid residues of tubulin β and tubulin α , respectively, are listed in Table 4.

-12-

TABLE 4

bTubA Residue	Eukaryotic β Tubulin Substitution	bTubB Residue	Eukaryotic α Tubulin Substitution
157	Ser or gly	106	His
160	Arg	107	Tyr
162	Glu	108	Thr
164	Pro	191	His
165	Asp	192	Thr, Ser or Ala
194	His	195	Glu or Asp
195	Gln	260	Tyr or Phe
197	Val or Leu	262	Arg
198	Glu or Gln	263	Gly, Ile or Val
199	Asn or His	389	Tyr
268	Arg	390	Ala or Ser
348	Glu	391	Lys
409	Asp	392	Arg
411	Met, Ser or Leu	399	Val
412	Glu	400	Gly
414	Thr, Val or Ser	401	Glu
415	Glu	404	Glu
418	Ser	405	Glu
419	Asn or Asp	406	Gly
421	Asn or Arg	407	Glu
422	Asp	409	Ser or Thr
425	Ser	410	Glu
426	Glu	413	Glu
429	Gln	414	Asp
431	Gln	417	Ala or Ser
432	Asp	419	Glu
		420	Lys or Arg
		421	Asp
		424	Glu
		425	Val
		426	Gly or Ala

[00020] Accordingly, the present invention embraces substitution or replacement of surface amino acid residues of prokaryotic tubulin A and tubulin B with the corresponding eukaryotic residues set forth in Table 4. In particular embodiments, the present invention embraces tubulin A (SEQ ID NO:7) and B (SEQ ID NO:8) proteins with the amino acid substitutions listed in Table 4. In accordance with this embodiment, the invention embraces

-13-

hybrid *Prostheco bacter*-eukaryotic tubulin proteins and a heterodimer composed of the same.

[00021] The C terminus of tubulin has been shown to be involved in cytoplasmic dynein and kinesin binding and processivity (Wang & Sheetz (2000) *Biophys J.* 78(4):1955-1964; Skiniotis, et al. (2004) *EMBO J.* 23(5):989-999), and binding microtubule-associated protein 2 or tau (Littauer, et al. (1986) *Proc. Natl. Acad. Sci. USA* 83(19):7162-6). Thus, in addition to the above-referenced amino acid substitutions or replacements of surface amino acid residues of prokaryotic tubulin A and tubulin B with corresponding eukaryotic residues, certain embodiments further embrace the addition or fusion of the C-terminal tail of eukaryotic tubulin to the C-terminus of the prokaryotic tubulin proteins. According to this invention, the C-terminus of eukaryotic tubulin α and tubulin β is intended to mean the last (i.e., C-terminal) 50, 40, 30, or 20 amino acid residues of eukaryotic tubulin α and tubulin β proteins. In one embodiment, the C-terminus of eukaryotic tubulin α is intended to include the last 13 to 20, 14 to 18, or 15 to 16 amino acid residues of a eukaryotic tubulin α protein. In another embodiment, the C-terminus of eukaryotic tubulin β is intended to include the last 15 to 25, 16 to 20, or 18 to 19 amino acid residues of a eukaryotic tubulin α protein. Exemplary C-termini of eukaryotic tubulin α include, but are not limited to, VDSVEGEGEEEGEEY (SEQ ID NO:9), ADSAEGDDEGDEY (SEQ ID NO:10), and VGTDSFEEENEGEREF (SEQ ID NO:11). Exemplary C-termini of eukaryotic tubulin β include, but are not limited to, ATADEQGGEFEEEGEEDDA (SEQ ID NO:12), ATADEQGGEFEEEGEEDDA (SEQ ID NO:13), ATAEFEEGFEFEEAEEFVA (SEQ ID NO:14), and ATAEFEEGFEFEEAEDDA (SEQ ID NO:15). Additional eukaryotic tubulin C-termini are known and readily obtained

-14-

from sequences available from sources such as GENBANK and EMBL databases. Preferably, the C-terminal 18 amino acid residues of eukaryotic tubulin β are added to the C-terminus of bTubA and the C-terminal 15 amino acid residues of eukaryotic tubulin α are added to the C-terminus of bTubB.

[00022] There are a variety of ways in which one can make the hybrid tubulin proteins of the invention. In one embodiment of this invention, a hybrid tubulin protein is prepared by introducing multiple amino acid substitutions simultaneously or consecutively introducing single amino acid substitutions into a prokaryotic tubulin protein. For convenience, substitutions in the amino acid sequence of native prokaryotic tubulin protein are usually made by introducing mutations into the corresponding nucleotide sequence of the DNA encoding native prokaryotic tubulin protein, for example by site-directed mutagenesis. Expression of the mutated DNA then results in production of the hybrid tubulin protein having the desired (non-native) amino acid sequence. Whereas any technique known in the art can be used to perform site-directed mutagenesis, e.g., as disclosed in Sambrook, et al. ((1989) *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, New York), oligonucleotide-directed mutagenesis is a preferred method for preparing the hybrid tubulin proteins of this invention. This method, which is well-known in the art (Zoller, et al. (1983) *Meth. Enzymol.* 100:4668-500; Zoller, et al. (1987) *Meth. Enzymol.* 154:329-350; Carter (1987) *Meth. Enzymol.* 154:382-403; Kunkel, et al. (1987) *Meth. Enzymol.* 154:367-382; Horwitz, et al. (1990) *Meth. Enzymol.* 185:599-611), is particularly suitable for making hybrid tubulin proteins.

-15-

[00023] The site-directed mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage, and plasmid vectors that contain a single-stranded phage origin of replication (Messing, et al. (1983) *Meth. Enzymol.* 101:20-78; Veira, et al. (1987) *Meth. Enzymol.* 153:3-11; Short, et al. (1988) *Nuc. Acids. Res.* 16:7583-7600). Replication of these vectors in suitable host cells results in the synthesis of single-stranded DNA that may be used for site-directed mutagenesis.

[00024] Of course, site-directed mutagenesis may be used to introduce multiple substitutions into a starting DNA. If the sites to be mutated are located close together, the mutations can be introduced simultaneously using a single oligonucleotide that encodes all of the desired mutations. If, however, the sites to be mutated are located some distance from each other (separated by more than about ten nucleotides), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.

[00025] In one method, a separate oligonucleotide is generated for each desired mutation. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions.

[00026] In an alternative method, two or more rounds of mutagenesis are used to produce the desired variant. The first round is as described for introducing a single mutation. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or

-16-

more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on.

[00027] PCR mutagenesis (Higuchi (1990) *PCR Protocols*, pp. 177-183, Academic Press; Vallette, et al. (1989) *Nucl. Acids Res.* 17:723-733) is also suitable for making the hybrid tubulins of the invention. Briefly, when small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in the template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, for example, the sequence of one of the primers includes the desired mutation and is designed to hybridize to one strand of the plasmid DNA at the position of the mutation; the sequence of the other primer must be identical to a nucleotide sequence within the opposite strand of the plasmid DNA, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone. See also,

-17-

Wagner, et al. (1991) *PCR Topics*, pp. 69-71, Springer-Verlag.

[00028] Another method for preparing hybrid tubulin proteins is cassette mutagenesis, which is based on the technique described by Wells, et al. (1985) *Gene* 34:315-323. The starting material is the plasmid (or other vector) carrying the DNA sequence to be mutated. The codon(s) in the starting DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the DNA. The plasmid DNA is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures, wherein the two strands of the oligonucleotide are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 5' and 3' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. The resulting plasmid contains the mutated DNA sequence.

[00029] The presence of mutation(s) in a DNA is determined by methods well-known in the art, including restriction mapping and/or DNA sequence analysis, e.g., by the dideoxy chain termination method of Sanger, et al. (1979) *Proc. Nat. Acad. Sci. USA* 72:3918-3921.

[00030] DNA encoding a hybrid tubulin of the invention is inserted into a replicable vector for further cloning or expression. "Vectors" are plasmids and other DNAs that are

-18-

capable of replicating within a host cell, and as such, are useful for performing two functions in conjunction with compatible host cells (a vector-host system). One function is to facilitate the cloning of the nucleic acid that encodes a hybrid tubulin, *i.e.*, to produce usable quantities of the nucleic acid. The other function is to direct the expression of a hybrid tubulin. One or both of these functions are performed by the vector in the particular host cell used for cloning or expression. The vectors will contain different components depending upon the function they are to perform.

[00031] To produce a hybrid tubulin, an expression vector will include DNA encoding the hybrid tubulin, as described above, operably linked to a promoter and a ribosome binding site. The hybrid tubulin then is expressed directly in recombinant cell culture, or as a fusion with a heterologous polypeptide, preferably a signal sequence or other polypeptide having a specific cleavage site at the junction between the heterologous polypeptide and the hybrid tubulin.

[00032] "Operably linked" refers to the covalent joining of two or more DNA sequences, by means of enzymatic ligation or otherwise, in a configuration relative to one another such that the normal function of the sequences can be performed. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are

-19-

contiguous and, in the case of a secretory leader, contiguous and in reading phase. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used, in conjunction with standard recombinant DNA methods.

[00033] In some embodiments the hybrid tubulin A protein and hybrid tubulin B protein of the invention are expressed individually in separate host cells. In other embodiments, the hybrid tubulin proteins of the invention are coexpressed in the same host cell, *e.g.*, from the same expression vector.

[00034] Prokaryotes (*e.g.*, *E. coli*, and other bacteria) are the preferred host cells for the initial cloning steps of this invention. They are particularly useful for rapid production of large amounts of DNA, for production of single-stranded DNA templates used for site-directed mutagenesis, and for DNA sequencing of the hybrids generated. Prokaryotic host cells also can be used for expression of DNA encoding hybrid tubulin proteins. Polypeptides that are produced in prokaryotic cells typically will be non-glycosylated.

[00035] In addition, the hybrid tubulin proteins of this invention can be expressed in eukaryotic host cells, including eukaryotic microbes (*e.g.*, yeast), plant cells, or cells derived from an animal or other multicellular organism (*e.g.*, Chinese hamster ovary cells, and other mammalian cells), or in live animals (*e.g.*, cows, goats, sheep).

[00036] Cloning and expression methodologies are well-known in the art. Examples of prokaryotic and eukaryotic host cells, and expression vectors, suitable for use in

-20-

producing the hybrid tubulin proteins of the present invention are, for example, those disclosed in WO 90/07572.

[00037] If prokaryotic cells or cells that contain substantial cell wall constructions are used as hosts, the preferred methods of transfection of the cells with DNA is the calcium treatment method described by Cohen et al. ((1972) *Proc. Natl. Acad. Sci.* 69:2110-2114) or the polyethylene glycol method of Chung et al. ((1988) *Nuc. Acids. Res.* 16:3580). If yeast are used as the host, transfection is generally accomplished using polyethylene glycol, as taught by Hinnen ((1978) *Proc. Natl. Acad. Sci. USA* 75:1929-1933). If mammalian cells are used as host cells, transfection generally is carried out by the calcium phosphate precipitation method of Graham, et al. ((1978) *Virology* 52:546) or Gorman, et al. ((1990) *DNA and Protein Eng. Tech.* 2:3-10). However, other known methods for introducing DNA into prokaryotic and eukaryotic cells, such as nuclear injection, electroporation, particle bombardment, *Agrobacterium*-mediated transformation, or protoplast fusion also are suitable for use in this invention.

[00038] Hybrid tubulin proteins preferably are secreted from the host cell in which it they are expressed, in which case the proteins are recovered from the culture medium in which the host cells are grown. In that case, it may be desirable to grow the cells in a serum free culture medium, since the absence of serum proteins and other serum components in the medium may facilitate purification of the hybrid tubulin proteins. If it is not secreted, then the hybrid tubulin proteins are recovered from lysates of the host cells. When the hybrid tubulin proteins are expressed in a host cell other than one of human origin, the hybrid tubulin proteins will be completely free of proteins of human origin. In any

-21-

event, it will be necessary to purify the hybrid tubulin proteins from recombinant cell proteins in order to obtain substantially homogeneous preparations of the hybrid tubulin proteins.

[00039] Generally, purification of a hybrid tubulin protein is accomplished by taking advantage of the differential physicochemical properties of the hybrid tubulin protein as compared to the contaminants with which it may be associated. For example, as a first step, the culture medium or host cell lysate is centrifuged to remove particulate cell debris. The hybrid tubulin protein thereafter is purified from contaminant soluble proteins and polypeptides, for example, by ammonium sulfate or ethanol precipitation, gel filtration (molecular exclusion chromatography), ion-exchange chromatography, hydrophobic chromatography, immunoaffinity chromatography (e.g., using a column containing anti-tubulin antibodies coupled to SEPHAROSE), cation exchange chromatography (WO 93/25670), reverse phase HPLC, and/or gel electrophoresis.

[00040] In a further embodiment of this invention, a hybrid tubulin protein will include one or more additional amino acid sequence mutations, tags, or other modifications, e.g., modifications that facilitate or block the assembly of the hybrid proteins into protofilament microtubules or facilitate or block interactions with associated proteins.

[00041] Antibodies to hybrid tubulin proteins of the invention are also contemplated. Such antibodies are produced by immunizing an animal with a hybrid tubulin protein or a fragment thereof, optionally in conjunction with an immunogenic polypeptide, and thereafter recovering antibodies from the serum of the immunized animals. Alternatively, monoclonal antibodies are prepared from cells of the immunized animal in conventional fashion. The

-22-

antibodies also can be made in the form of chimeric (e.g., humanized) or single chain antibodies or Fab fragments, using methods well-known in the art. Preferably, the antibodies will bind to the hybrid tubulin protein but will not substantially bind to (i.e., cross react with) other native tubulin proteins (such as native human, bovine, or prokaryotic tubulin). The antibodies can be used in methods relating to the localization and assembly of the hybrid tubulin proteins. Immobilized antibodies are particularly useful in the purification of the hybrid tubulin proteins, for example from recombinant cell cultures.

[00042] The hybrid tubulin proteins of the invention find application in studying tubulin dimerization, protofilament formation, and motor protein interactions as well as in identifying agents that modulate the activity of tubulin.

[00043] It is contemplated that the hybrid tubulins of the invention can be used to generate a crystal structure of tubulin alone or in combination with associated proteins (e.g., kinesin, dynein or other microtubule associated proteins (MAPs)). Once the three-dimensional structure of the hybrid tubulin is determined, a potential modulatory agent can be examined through the use of computer modeling using a docking program such as GRAM, DOCK, or AUTODOCK (Dunbrack, et al. (1997) *Folding & Design* 2:27-42). This procedure can include computer fitting of potential agents to the tubulin dimer to ascertain how well the shape and the chemical structure of the potential ligand will interact with the tubulin dimer. Computer programs can also be employed to estimate the attraction, repulsion, and steric hindrance of the test agent. Generally the tighter the fit (e.g., the lower the steric hindrance, and/or the greater the attractive force) the better substrate the agent will be since these properties are consistent with a

-23-

tighter binding constraint. Furthermore, the more specificity in the design of a potential test agent the more likely that the agent will not interfere with related mammalian proteins. This will minimize potential side-effects due to unwanted interactions with other proteins.

[00044] In addition to *in silico* screening, the invention also embraces *in vitro* and *in vivo* screening of test agents which involves contacting the hybrid *Prosthecobacter*-eukaryotic tubulin heterodimer of the invention with a test agent and determining whether the test agent modulates the activity of the *Prosthecobacter*-eukaryotic tubulin heterodimer as compared to a control, e.g., a heterodimer not contacted with the test agent. Tubulin activities which can be monitored include, but are not limited to, dimerization, GTPase activity, polymerization into protofilaments, and/or interaction with associated proteins. Test agents which can be screened in accordance with the present invention can be from any source and can be any type of molecule, e.g., protein, carbohydrate, nucleic acid, small organic compound, natural product, antibody, and the like. Agents identified by the method of the invention find application in the treatment of diseases or conditions such as cancer.

[00045] The invention is described in greater detail by the following non-limiting examples.

Example 1: Hybrid Bacterial-Bovine Tubulins

[00046] Using a model of the kinesin motor domain-microtubule complex derived from cryo-EM reconstruction (Kif1a-AMPPNP, Protein Data Base ID 2HXF) (Kikkawa & Hirokawa (2006) *EMBO J.* 25:4187-4194), BtubA and BtubB (PDB, 2BTQ) were aligned with α and β tubulin. It should be noted that BtubA is most homologous to β -tubulin, and BtubB

-24-

is most homologous with α -tubulin. Residues in BtubA/B residues within 8 Å of the docked kinesin motor domain were identified. In so far as it was desired to avoid any mutations that would result in misfolding, or even decrease the folding efficiency of the hybrid genes, all of these residues were individually checked to ensure that they were significantly solvent exposed and that they did not participate in any interactions with the core amino acids. Following this analysis, 57 amino acids were identified for mutagenesis, 26 in BtubA in order to make its surface like β -tubulin, and 31 in BtubB to make it resemble α -tubulin. A structural alignment of BtubA with β -tubulin using the protein structure comparison service SSM at European Bioinformatics Institute (Krissinel & Henrick, 2004) *Acta Crystallogr. D Biol. Crystallogr.* 60:2256-2268), produced a root mean square deviation (RMSD) of 1.75 Å over 397 amino acid α -carbons. A similar alignment of BtubB with α -tubulin resulted in an RMSD of 1.66 Å over 360 amino acid α -carbons. Due to this close alignment, it was contemplated that the overall core of the proteins were very similar, and therefore surface mutations would produce an interface closely resembling eukaryotic tubulin. Following design, these hybrid tubulins were modeled in order to assess whether the shape and surface charge characteristics would resemble bovine tubulin. This analysis indicated that the electrostatic surface of the hybrid tubulin very closely resembled that of bovine tubulin. Note that the bacterial tubulin template, contoured in the same manner, looks very different. No energy minimization was performed, so the specific position of side chains was approximate, but the overall charge characteristics were expected to be quite accurate.

-25-

[00047] These hybrid genes, (named HtubA and HtubB for "Hybrid tubulin A and B") were then cloned into *E. coli* pET-based expression vectors and the overexpressed proteins were purified using a combination of standard protein purification strategies including ion exchange and Ni-NTA affinity chromatography. Both HtubA and HtubB constructs contained a polyhistidine purification tag, and the HtubA protein also contained an N-terminal thioredoxin tag. Yields of purified protein were 10 mg HtubA per 1 L starting culture and 5 mg HtubB per 1 L starting culture. Analyses of the activity of HtubA/B indicated the following.

[00048] When purified HtubA and HtubB proteins were mixed in a 1:1 stoichiometric ratio and subjected to gel filtration chromatography, they eluted from the column at an apparent molecular weight of a dimer. These results indicate that mixture of HtubA/B protein is associating, while not polymerizing.

[00049] When the Eg5 (a kinesin-5) motor domain was mixed in a 1:1 stoichiometric ratio with HtubA/B, and subjected to gel filtration chromatography in the absence of additional salt and ATP, the kinesin-HtubA/B complex eluted from the column at an apparent molecular weight of a trimeric complex. These results indicate that a kinesin motor can bind the HtubA/B dimer.

[00050] After adding additional salt and ATP to the Eg5-HtubA/B complex, the proteins were resolved over a gel filtration column, and the kinesin was found to have dissociated from the HtubA/B complex. These results are consistent with how a kinesin interacts with eukaryotic microtubules.

[00051] The Eg5-HtubA/B complex was rapidly mixed with fluorescent MANT-ATP in a stopped-flow instrument. This

-26-

experiment was designed to monitor the kinetics of ATP binding to kinesin in the absence and presence of HtubA/B. In the absence of HtubA/B, the rate of ATP binding was 0.5-1 sec⁻¹ and in the presence of eukaryotic microtubules, the rate of ATP binding was 25-30 sec⁻¹. When the kinesin-HtubA/B complex was mixed with MANT-ATP, a rate of ATP binding of 265 ± 14 sec⁻¹ was observed. These results indicate that the HtubA/B complex stimulates the rate of ATP binding to kinesin.

[00052] Taken together, these results indicate that hybrid bacterial-eukaryotic tubulin protein can be expressed and purified, fold properly in bacterial expression systems, and bind to a kinesin motor domain in a manner similar to that observed for eukaryotic microtubules.

Example 2: Characterization of Hybrid Bacterial-Bovine Tubulins

[00053] Circular dichroism (CD) spectroscopy is used to demonstrate that HtubA/B resembles bovine tubulin. As the α and β isoforms of bovine tubulin are not stable when separated, HtubA and HtubB are compared alone and in complex with dimeric bovine tubulin under non-polymerizing conditions. Analytical gel filtration and analytical ultracentrifugation are also used to measure complex formation between HtubA and HtubB.

[00054] The GTPase activity of HtubA, HtubB, and HtubA/B is determined by measuring the concentration of evolved phosphate, using an improved sensitivity malachite green assay (Geladopoulos, et al. (1991) *Analytical Biochemistry* 192:112-116) as well as coumarin-labeled phosphate binding protein (MDCC-PBP) coupled assay (Brune, et al. (1994) *Biochemistry* 33:8262-8271) in a stopped-flow instrument. For the MDCC-PBP assay, purified HtubA, HtubB, or HtubA/B

-27-

are incubated with GTP for increasing time domains, then quenched with acid, followed by neutralization with base. In order to quantify the background level of Pi in the reaction, a zero time point is performed by mixing Htub with acid, followed by addition of GTP and base. Pi is quantified by rapidly mixing the reaction contents at each time point with MDCC-PBP in a stopped-flow instrument (Cochran, et al. (2009) *Cell* 136:110-122).

[00055] Polymer formation of HtubA/B is analyzed by pelleting assays. The HtubA construct contains an N-terminal thioredoxin tag in order to assist in expression and block polymerization. Although preliminary data indicate this is not interfering with intra-dimer formation, polymer formation will require HtubA without the thioredoxin tag. This construct is in the background of a pET32b plasmid (Novagen). As such, a thrombin cleavage site follows the thioredoxin tag and polyhistidine purification tag, thereby facilitating the removal of the tag. In order to assay protofilament formation, GTP is added to stimulate polymerization of various molar ratios of HtubA and HtubB, and the reactions are centrifuged in a TLA100 rotor (Beckman Coulter) for 20 minutes at 250,000 g at 20°C. Samples of the supernatant and pellet fractions are resolved by SDS-PAGE. HtubA/B polymer formation can also be analyzed by static 90° light scattering experiments using a fluorimeter with excitation and emission wavelengths set to 350 nm and a slit width of 3 nm. GTP is added to initiate polymerization and the critical concentration for protofilament bundle formation is determined.

[00056] Negative stained electron microscopy is then used to image formation of the HtubA/B protofilament twisted pairs and bundles. Time course EM experiments are performed to

-28-

determine the early stages of HtubA/B filament formation at low HtubA/B concentrations.

[00057] HtubA and HtubB proteins are used individually, and as a dimer, in X-ray diffraction studies to determine their high resolution structure. The conditions for crystallization for BtubA/B (Schlieper, et al. (2005) *Proc. Natl. Acad. Sci. USA* 102:9170-9175) are initially used to design a matrix for crystal screening. Standard hanging drop vapor diffusion methods are used and a number of different screening kits are employed, including the standard sparse matrix sampling conditions as well as polyethylene glycol (PEG) screens. The structures are solved using molecular replacement using existing BtubA/B structures as search models. The high resolution structural analysis of the HtubA/B system alone provides a foundation for addressing any conformational changes in tubulin upon kinesin binding as well as assisting in further surface re-design to achieve a more eukaryotic-like tubulin that can be produced in bacteria.

Example 3: Detailed Structural Characterization of HtubA/B-Motor and HtubA/B-MAP Interactions

[00058] Atomic resolution crystal structures of a kinesin motor in complex with tubulin as well as microtubule binding domain of cytoplasmic dynein in complex with HtubA/B are determined. Further studies can also utilize the HtubA/B proteins to investigate the structures of other MAPs in complex with HtubA/B.

[00059] Analytical gel filtration and analytical ultracentrifugation are used to measure complex formation between HtubA•HtubB as well as between the ternary complex HtubA•HtubB•kinesin. As different kinesin motors have different behaviors and binding affinities to tubulin,

-29-

several different kinesin motor domain constructs are used for this analysis. Such constructs include, e.g., conventional kinesin (kinesin-1), Eg5 (kinesin-5), Kif18a (kinesin-8), NOD (kinesin-10), MCAK (kinesin-13), Ncd (kinesin-14), and Costal2 (an unclassified kinesin). Each of these motor domains are incubated with preformed HtubA/B and then analyzed using the techniques described above for stability.

[00060] Using the MDCC-PBP coupled assay described herein, ATPase stimulation is measured when each of the motor domains incubated with the HtubA/B complex. This is then compared to the ATPase stimulation of the motors in the presence of bovine dimeric tubulin. Other presteady-state kinetic parameters of kinesin in complex with HtubA/B are also measured including rates of ATP and ADP binding and the release rates of ADP and Pi. As described herein, removal of the N-terminal thioredoxin tag should result in the HtubA/B dimer forming polymeric protofilaments similar to those observed for native BtubA/B. Therefore, the filament stimulated ATPase of the various motors is characterize and compared to that of the dimer stimulated motor ATPase.

[00061] During the process of the characterization studies described herein, it will become clear which motors bind to HtubA/B, and which conditions favor formation and stabilization of this complex. In this regard, it may be necessary to use the thioredoxin tagged HtubA to inhibit polymerization. Alternately, mutants in the dimer-dimer interface can be engineered that would block polymerization.

[00062] Given that structures of many of the kinesin motor domains are available, and that the crystal structure of BtubA/B is also available, solving the structure will

-30-

likely be possible using molecular replacement phasing. Alternatively, the proteins can be expressed and purified using selenomethionine for MAD, SAD, or SIRAS phasing.

[00063] The previously crystallized dynein microtubule binding domain (MTBD) was expressed as a fusion with seryl-tRNA synthetase (SRS) containing 3 heptads in the antiparallel stalk region (Carter, et al. (2008) *Science* (New York, NY) 322:1691-1695). The microtubule binding domain was 167 amino acids and was a stable, folded extension from the SRS fusion partner. The microtubule binding domain can be PCR amplified from mouse dynein cDNA and the truncated construct can be cloned into *E. coli* pET-based vectors for overexpression and purification. The purified microtubule binding domain protein is analyzed by CD spectroscopy and analytical ultracentrifugation to ensure proper structure, and is functionally characterized by microtubule co-sedimentation experiments. The microtubule binding domain is then mixed with HtubA/B to obtain crystals and the structure of the MTBD-HtubA/B complex at high resolution is determined.

[00064] With the HtubA/B dimer readily available, it is now straightforward to investigate its association with other microtubule associated proteins. As indicated, many of these proteins interact with microtubules through multiple binding sites. As such, microtubule binding domain constructs can be cloned, expressed, and purified for these experiments. Initial targets would be the microtubule binding motifs of tau, MAP2, MAP4, the DCX domain of doublecortin and the human spastin protein, including its AAA domain and its microtubule binding domain. In addition, the interaction of +TIP-HtubA/B complexes will also be determined.

Example 4: Design and Characterization of a Mini-Protofilament

[00065] The HtubA/B dimer can be further engineered to form a mini-protofilament composed of an end-to-end dimer of HtubA/B dimers. Such a tetramer will allow for the investigation of motor protein and MAP interactions that involve two binding sites at the intradimer interface, and will also allow for the identification and characterization of interactions at the interdimer interface.

[00066] The HtubA/B dimer exemplified herein is blocked from polymerizing at the minus end by the presence of an N-terminal thioredoxin tag on HtubA (HtubA/B-TRX) and removal of this tag by protease cleavage or by expressing the HtubA without the tag results in HtubA/B dimer that can polymerize into protofilaments. In contrast, blocking polymerization at the plus end is more complicated as neither the N- nor C-terminus of HtubB is located in a position such that a tag would block further addition of dimer at the plus end. Therefore, site-directed mutagenesis is used at the plus-end binding interface of HtubB in order to block polymerization. This mutant HtubB would still be able to form normal interactions with HtubA at the minus-end interface, allowing formation of an HtubA/B dimer that is unable to polymerize (hereafter referred to as HtubA/B+). A similar approach has resulted in non-polymerizing mutant actin produced in a Sf9 baculovirus expression system (Joel, et al. (2004) *Biochemistry* 43:11554-11559).

[00067] This HtubA/B+ dimer is then mixed with the HtubA/B-TRX dimer. As these two dimer constructs have a mutually compatible interface, they will form a tetramer containing two intradimer interfaces and one interdimer interface (HtubA/B/A/B). If the thioredoxin tag is shown to interfere

-32-

with complex formation, a similar mutagenic approach could be taken in order to make an HtubA/B dimer blocked from polymerizing at the minus end.

[00068] The mechanistic characterizations described herein for the initial HtubA/B-TRX dimer alone and in complex with kinesin motors and MAPs is repeated with the mini-protofilament. Given that kinesins can bind to adjacent tubulin dimers, the HtubA/B/A/B tetramer will be able to form a complex with dimeric kinesins. This is characterized by gel filtration analysis as described herein for dimeric constructs of kinesin-1 and kinesin-5. Complex formation allows for high resolution structural studies to be carried out. A similar approach can be taken in order to characterize constructs of MAPs, such as tau, with two microtubule binding domains.

[00069] The surface engineering of the HtubA/B binding interface involved only residues located within 8 Å of the docked kinesin motor domain. While these include virtually the entire surface at the intradimer interface, residues at the interdimer interface formed in the HtubA/B/A/B tetramer will still contain surface residues from the original BtubA/B proteins. This should neither affect formation of the tetramer nor the dimer binding experiments described herein, but it would present a non-eukaryotic surface at this interface. Therefore, the remainder of the surface exposed residues in the region can be mutated to resemble eukaryotic tubulin, thereby producing an HtubA/B/A/B tetramer with a completely eukaryotic surface. To form a protofilament with this complete interface, additional surface mutations can be introduced into the untagged HtubA protein.

[00070] With HtubA/B dimer, HtubA/B/A/B tetramer, and HtubA/B protofilaments available, binding of motor proteins

-33-

as well as other MAPs can be compared. For example, it will be possible to measure differential binding of the complete or fractionated MAP pool that is obtained during a prep of bovine tubulin. During this procedure, a large number of MAPs are separated from purified tubulin and discarded. This pool of MAPs can be assayed to identify differences in binding to HtubA/B dimers, tetramers, and protofilaments. While this will identify a number of known proteins and MAPs, comparison with each other and with bovine microtubules will highlight differences in binding modes, as well as distinguishing between MAPs that bind to the inside/outside of microtubules, or in between adjacent protofilaments. Proteins that bind in specific or unusual ways can then be identified by mass spectrometry analysis.

-34-

What is claimed is:

1. An isolated hybrid *Prostheco bacter*-eukaryotic tubulin A protein comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of *Prostheco bacter* tubulin A, wherein the surface amino acid residues of *Prostheco bacter* tubulin A have been replaced with the corresponding surface amino acid residues of eukaryotic tubulin β .

2. The hybrid protein of claim 1, wherein the *Prostheco bacter* tubulin A comprises SEQ ID NO:7.

3. The hybrid protein of claim 1, wherein the eukaryotic tubulin β is mammalian.

4. The hybrid protein of claim 1, wherein the surface amino acid residues of *Prostheco bacter* tubulin A are set forth in Table 2.

5. The hybrid protein of claim 1 comprising the amino acid substitutions set forth in Table 4.

6. The hybrid protein of claim 1, further comprising a eukaryotic C-terminus.

7. The hybrid protein of claim 6, wherein the eukaryotic C-terminus is selected from the group of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15.

8. The hybrid protein of claim 1, further comprising a hybrid *Prostheco bacter*-eukaryotic tubulin B protein with an amino acid sequence having at least 90% sequence identity

-35-

with the amino acid sequence of *Prostheco bacter* tubulin B, wherein the surface amino acid residues of *Prostheco bacter* tubulin B have been replaced with the corresponding surface amino acid residues of eukaryotic tubulin α .

9. The hybrid protein of claim 10, wherein the *Prostheco bacter* tubulin B comprises SEQ ID NO:8.

10. The hybrid protein of claim 8, wherein the eukaryotic tubulin α is mammalian.

11. The hybrid protein of claim 8, wherein the surface amino acid residues of *Prostheco bacter* tubulin B are set forth in Table 2.

12. The hybrid protein of claim 8 comprising the amino acid substitutions set forth in Table 4.

13. The hybrid protein of claim 8, wherein the hybrid *Prostheco bacter*-eukaryotic tubulin B protein further comprises a eukaryotic C-terminus.

14. The hybrid *Prostheco bacter*-eukaryotic tubulin B protein of claim 13, wherein the eukaryotic C-terminus is selected from the group of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.

15. An isolated hybrid *Prostheco bacter*-eukaryotic tubulin heterodimer comprising amino acid sequences having at least 90% sequence identity with the amino acid sequences of SEQ ID NO:7 and SEQ ID NO:8, wherein the surface amino acid residues of SEQ ID NO:7 and SEQ ID NO:8 have been replaced with the corresponding surface amino

-36-

acid residues of eukaryotic tubulin β and tubulin α , respectively.

16. The hybrid *Prostheco bacter*-eukaryotic tubulin heterodimer of claim 15, comprising the amino acid substitutions set forth in Table 4.

17. The hybrid *Prostheco bacter*-eukaryotic tubulin heterodimer of claim 15, further comprising eukaryotic C-termini.

18. An isolated nucleic acid molecule encoding the hybrid *Prostheco bacter*-eukaryotic tubulin A protein of claim 1.

19. An isolated nucleic acid molecule encoding the hybrid *Prostheco bacter*-eukaryotic tubulin B protein of claim 8.

20. An isolated host cell comprising the isolated nucleic acid molecule of claim 18.

21. The isolated host cell of claim 20, further comprising an isolated nucleic acid molecule encoding a hybrid *Prostheco bacter*-eukaryotic tubulin B protein with an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:8, wherein the surface amino acid residues of SEQ ID NO:8 have been replaced with the corresponding surface amino acid residues of eukaryotic tubulin α .

-37-

22. The isolated host cell of claim 20, wherein said host cell is selected from the group of bacteria, yeast, filamentous fungi, and plant cells.

23. A method for identifying an agent that modulates the activity of tubulin comprising contacting the hybrid *Prostheco bacter*-eukaryotic tubulin heterodimer of claim 15 with a test agent and determining whether the test agent modulates the activity of the *Prostheco bacter*-eukaryotic tubulin heterodimer as compared to a control, thereby identifying an agent that modulates the activity of tubulin.

2/2

TUBULIN B

Pdej VREILSIHVGQCGNQIADSFWRLLALREHGLTEAGTLKEGSNAAANSNMEVFFHKVRDGY
 Pdeb MREILSIHVGQCGNQIADSFWRLLALKEHGLTETGTLKEGANAAANSNDLEVFFHVRREGKY
 Pvan MREILSIHVGQCGNQIADRFWRLLVREHGLTEAGTPKEGTNVAANANMEVFFHKVRDGY
 :*****
 Cons. XREILSIHVGQCGNQIADXFWRLXLXEHGLTEXGTXKEGXNXXAANXXXEVFFHXVRXGKY

Pdej VPRAVLVDLEPGVIARIEGGDMSQLFDESSIVRKIPGAANNWARGYNVEGEKVIDQIMNV
 Pdeb VPRAVLIDLEPGVIGRIESGDMSKLFDESCIVRKIPGAANNWARGYHAEGKRVIDQIMNV
 Pvan IPRAILVDLEPGVIARIEGGDMAQLFDESCIIRKIPGAANNWARGYNVEGERIIDQIMNV
 :***:***:*****.***.***:*****.***:*****:***:*****
 Cons. XPRAXLXDLEPGVIXRIEXGDMXXLFDESXIXRKIPGAANNWARGYXXEGXXXIDQIMNV

Pdej IDSAVEKTKGLQGFLMTHSIGGGSGSGLGSLILERLRQAYPKKRIFTFSVVPSPPLISDSA
 Pdeb IDSAVEKTKGLQGFLMTHSIGGGSGSGLGSLILERLRQAYPKKRIFTFSVVPSPPLISDSA
 Pvan IDAAVEKTKSLQGFLMTHSIGGGSGSGLGSLILERLRQAYPKKRIFTFSVAPSPPLISDSA
 :***.*****:*****:*****:*****:*****:*****
 Cons. IDXAVEKTKXLQGFLXTHSIGGGSGSGLGSLILERLRQAYPKKRIFTFSVXPSPPLISDSA

Pdej VEPYNAILTLQRILDNADGAVLLDNEALFRIAKAKLNRSPTYMDLNNIIALIVSSVTASL
 Pdeb VEPYNAILTLKRLLDHADGSVLLDNEALFRIAKXKLNRSPYMDLNNIIALIVSSVTASL
 Pvan VEPYNAILTLQRILDNADAADVLLDNEALFRIAKSKLHRSPNYMDLNNIIALIMSSVTASL
 *****:***:***:***:*****:***:***.*****:*****:*****
 Cons. VEPYNAILTLXRLDNADXXVLLDNEALFRIAKXKLXRSPTYMDLNNIIALXSSVTASL

Pdej RFPGKLNTDLSEFVTNLVPFPGNHFLTASFAPMRGAGQEGQVRTNFPDLARETFAQDNFT
 Pdeb RFPGKLNTDLSEFVTNLVPFPGNHFLTASFAPMRTADESQVRMSFPELARETFAQDNFT
 Pvan RFPGKLNTDLGEYVTNLVPFPGNHFLTASFAPMRAPGQEGQVRINFPDLARETFAQDNFT
 *****:***:*****:*****:***:***.*****:*****:*****
 Cons. RFPGKLNTDLXEXVTNLVPFPGNHFLTASFAPMRXXXEXQVRXXFPXXARETFAQDNFT

Pdej AAIDWQQGVYLAASALFRGDVKAQVDENMATIRKSLNYASYMPASGGLKLGYAETAPEG
 Pdeb AEIDWQNGVYLAASALFRGEVKAQVDENMATIRKELNYASYMPASGGLKLGYAETAPEG
 Pvan AAIDWTNGVYLSACALFRGDVKAQVEENMAAIRKSLNFASYVPT--GVKLGVAETAPEG
 * *** :***:***:*****:***:***:***:***:***:***:***:***:***
 Cons. AXIDWXXGVYLAAXALFRGXVKAQVXENMAXIRKXLNXASYXPXXGXLKLYAETAXEX

Pdej FASSGLALVNHTGIAAVFERLIAQFDIMFDNHAYTHWYENAGVSRDMMAKARNQIATLAQ
 Pdeb FASSGLALVNHTGISAVFERLIGQFDIMFDNHAYTHWYENAGVSRDQMAVARDQIANLAL
 Pvan FASSGLALVNHTGIAAVFERLINNFDIMFDNHAYTHWYENNGVSRDMMAHARNTIVNLAQ
 *****:*****:*****:*****:*****:*****:*****:***:***
 Cons. FASSGLALVNHTGIXAVFERLIXXFDIMFDNHAYTHWYENXGVSRDXMAXARXXIXXLAX

Pdej SYRDAS (SEQ ID NO:2)
 Pdeb SYRDAS (SEQ ID NO:6)
 Pvan SYRDAS (SEQ ID NO:4)

 Cons. SYRDAS (SEQ ID NO:8)

FIG. 1B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/31569

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07K 14/00; C40B 30/08 (2010.01)

USPC - 530/350; 506/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC: 530/350; 506/11

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC: 530/350; 506/11; 536/23.7 (text search)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Electronic data bases searched: PubWEST (EPAB, JPAB, PGPB, USPT); Google Scholar; GenCore Sequence Search (AA)
Search terms: tubulin, BtubA, BtubB, FtsZ, Prosthecobacter sp., hybrid tubulin, chimeric tubulin, prokaryotic-eukaryotic tubulin, cytoskeleton, tubulin protein engineering, SEQ ID NOS: 7-15

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	UNIPROTKB/SWISS-PROT. Q8GCC5. [online] 1 March 2003 [retrieved 24 June 2010]. Available on the internet <URL: http://www.uniprot.org/uniprot/Q8GCC5 >. Especially pg 1-2.	1-23
A	BERTRAND et al. Folding, stability and polymerization properties of FtsZ chimeras with inserted tubulin loops involved in the interaction with the cytosolic chaperonin CCT and in microtubule formation. J Mol Biol 11 February 2005 Vol 346 No 1 Pages 310-330. Especially abstract, pg 320 fig 1B, pg 321 left col para 2,	1-23
A	SCHLIEPER et al. Structure of bacterial tubulin BtubA/B: evidence for horizontal gene transfer. Proc Nat Acad Sci 28 June 2005 Vol 102 No 26 Pages 9170-9175. Especially abstract, pg 9170 left col para 1.	1-23
A	BOND et al. A chicken-yeast chimeric beta-tubulin protein is incorporated into mouse microtubules in vivo. Cell 14 February 1986 Vol 44 No 3 Pages 461-468.	1-23
A	SONTAG et al. In vitro assembly and GTP hydrolysis by bacterial tubulins BtubA and BtubB. J Cell Bio 25 April 2005 Vol 169 No 2 Pages 233-238.	1-23

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 June 2010 (24.06.2010)

Date of mailing of the international search report

20 JUL 2010

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774